Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	65 people with a suspected first episode of PCP; 49 people with confirmed diagnoses (only those with confirmed diagnoses were evaluated further)	Rate of adverse effects requiring a change in treatment 21 days 6/27 (22%) with clindamycin–primaquine 4/22 (18%) with TMP–SMX	P = 1.0		Not significant
RCT 3-armed trial	256 people with suspected PCP; 181 people with confirmed diagnoses (only those with confirmed diagnoses were evaluated further)	Dose-limiting toxicity 19/58 (33%) with clindamycin–primaquine 23/64 (36%) with TMP–SMX	P >0.2 for clindamycin v TMP-SMX		Not significant
RCT	116 people with suspected PCP; 87 people with confirmed diagnoses (only those with confirmed diagnoses were evaluated further)	Serious adverse effects primarily haematological 13/45 (29%) with clindamycin–primaquine 21/42 (50%) with TMP–SMX	P = 0.04	Effect size not calculated	clindamycin–primaquine